"PSOGEN:Effect adalimumab op zelfbeeld en seksueel functioneren bij matige en ernstige psoriasis van de anogenitale regio; prospectief, open label pilot onderzoek"

Published: 29-04-2009 Last updated: 05-05-2024

The objective is to assess the effect of adalimumab on selfconfidence and sexuality of patients with anogenital psoriasis.

Ethical review Approved WMO **Status** Recruiting

Health condition type Epidermal and dermal conditions

Study type Observational non invasive

Summary

ID

NL-OMON33188

Source

ToetsingOnline

Brief title

PSOGEN

Condition

• Epidermal and dermal conditions

Synonym

Psoriasis, scaling skin condition

Research involving

Human

Sponsors and support

Primary sponsor: Academisch Medisch Centrum

Source(s) of monetary or material Support: Abbott, Dit betreft een investigator initiated

door farmaceut gesponsord onderzoek

Intervention

Keyword: Adalimumab, Anogenitaal, Psoriasis

Outcome measures

Primary outcome

Lower scores on the measuring questionnaires.

Secondary outcome

None

Study description

Background summary

Psoriasis is a chronic inflammatory disease of the skin of unknown etiology. About 2-3% of the world population is affected by it. It is accompanied by heavy psychological burden. Altough psoriasis usually manifests on knees, elbows and the head, lesions in anogenital region are frequently seen. There are indications that the experience of sexuality can be nefatively influenced by it. On assessment of severity of psoriasis this is not taken into account. It is to be expected that this problem will improve with treatment of psoriasis. Validated questionnaires exist for evaluation of sexuality, self confidence and relationships: DS-c (inventory of depressive symptomatology), SEAR (Self-Esteem and Relationship), IIEF (International Index of Erectile Dysfunction) en FSFI(Female Sexual Function Index). They have been designed to measure the problems we are trying to assess. The PSOGEN questionnaire is designed by the study team and will show difference in how ano-genital psoriasis versus psoriasis in other body sites is experienced by the patients. Also the way in which patients grade the importance of sexuality and intimacy can be expressed by this instrument.

Study objective

The objective is to assess the effect of adalimumab on selfconfidence and

2 - "PSOGEN:Effect adalimumab op zelfbeeld en seksueel functioneren bij matige en er ... 7-05-2025

sexuality of patients with anogenital psoriasis.

Study design

This is a prospective study conducted in two hospitals in Netherlands. It is a pilot which will eventually lead to a controlled double blind trial.

Study burden and risks

Filling in the questionnares and physical and psychological examination cost time.

No benefit to patients is to be expected from this study.

Contacts

Public

Academisch Medisch Centrum

gk016 Burg. 's Jacobplein 51 3015 CE, Rotterdam NL

Scientific

Academisch Medisch Centrum

gk016 Burg. 's Jacobplein 51 3015 CE, Rotterdam NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years) Elderly (65 years and older)

Inclusion criteria

- -Having psoriasis of the anogenital region
- -The patient will be treated with adalimumab by attending physician

Exclusion criteria

- -Younger than 18
- -Homosexual
- -Unwilling to participate

Study design

Design

Study phase: 4

Study type: Observational non invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Diagnostic

Recruitment

NL

Recruitment status: Recruiting
Start date (anticipated): 17-09-2010

Enrollment: 20

Type: Actual

Medical products/devices used

Registration: No

Product type: Medicine

Brand name: Humira

Generic name: Adalimumab

Registration: Yes - NL intended use

Ethics review

Approved WMO

Date: 29-04-2009

Application type: First submission

Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam

(Rotterdam)

Approved WMO

Date: 05-10-2009

Application type: First submission

Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam

(Rotterdam)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID

EudraCT EUCTR2009-011625-13-NL

CCMO NL26555.078.09